1. Home
  2. EVN vs AKBA Comparison

EVN vs AKBA Comparison

Compare EVN & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Municipal Income Trust

EVN

Eaton Vance Municipal Income Trust

HOLD

Current Price

$10.31

Market Cap

430.6M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.39

Market Cap

380.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVN
AKBA
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
430.6M
380.4M
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
EVN
AKBA
Price
$10.31
$1.39
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$5.75
AVG Volume (30 Days)
72.4K
2.4M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.59
$1.14
52 Week High
$11.23
$4.08

Technical Indicators

Market Signals
Indicator
EVN
AKBA
Relative Strength Index (RSI) 33.52 51.41
Support Level $10.27 $1.30
Resistance Level $11.15 $1.55
Average True Range (ATR) 0.13 0.07
MACD -0.06 -0.01
Stochastic Oscillator 26.17 32.69

Price Performance

Historical Comparison
EVN
AKBA

About EVN Eaton Vance Municipal Income Trust

Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: